Cardinal Health 2015 Annual Report Download - page 90

Exhibit 99.1
Statement Regarding Forward-Looking Information
As used in this exhibit, “we,” “our,” “us” and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise.
Our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended June 30, 2015 (the “2015
Form 10-K”), our quarterly reports on Form 10-Q or our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well
as our news releases or any other written or oral statements made by or on behalf of us, may include, directly or by incorporation by reference, forward-
looking statements that reflect our current view (as of the date the forward-looking statement is first made) about future events, prospects, projections
or financial performance. The matters discussed in these forward-looking statements are subject to certain risks and uncertainties that could cause
actual results to differ materially from those projected, anticipated or implied in or by such statements. These risks and uncertainties include:
• competitive pressures in the markets in which we operate, including pricing pressures;
• increasing consolidation in the healthcare industry, which could give the resulting enterprises greater bargaining power and may increase pressure
on prices for our products and services;
• uncertainties due to government healthcare reform;
• changes to the prescription drug reimbursement formula and related reporting requirements for generic pharmaceuticals under Medicaid;
• material reductions in purchases, non-renewal or early termination of contracts, or delinquencies or defaults by key customers;
• risks associated with the generic pharmaceutical sourcing venture with CVS Health Corporation, including those relating to our ability to realize
and maintain the benefits from the sourcing venture;
• actions of regulatory bodies and other governmental authorities, including the U.S. Drug Enforcement Administration ("DEA"), the U.S. Food and
Drug Administration and other agencies within the U.S. Department of Health and Human Services, including the Centers for Medicare and Medicaid
Services, the Office of Inspector General and the Office for Civil Rights, the U.S. Nuclear Regulatory Commission, the U.S. Federal Trade
Commission, the U.S. Customs and Border Protection, various state boards of pharmacy, state controlled substance agencies, state health
departments, state insurance departments, state Medicaid departments or comparable regulatory bodies or governmental authorities or foreign
equivalents that could delay, limit or suspend product development, manufacturing, distribution, importation or sales or result in warning letters,
recalls, seizures, injunctions or monetary sanctions;
• the possibility of civil fines levied against us (in excess of the reserve we have accrued) by the U.S. Department of Justice for conduct covered by
the settlement agreement that we entered into in connection with the DEA's suspension of our Lakeland, Florida distribution center's registration
to distribute controlled substances;
• the loss of, or default by, one or more key suppliers for which alternative suppliers may not be readily available;
• unfavorable changes to the terms of key customer or supplier relationships, or changes in customer mix;
• changes in manufacturers' pricing, selling, inventory, distribution or supply policies or practices;
• changes in hospital buying groups or hospital buying practices;
• changes in the frequency or magnitude of brand or generic pharmaceutical price appreciation, restrictions in the amount of inventory available to
us, or changes in the timing or frequency of generic launches or the introduction of brand pharmaceuticals;
• uncertainties relating to market conditions for pharmaceuticals;
• uncertainties relating to demand for our products and services;
• changes in distribution or sourcing models for pharmaceutical and medical/surgical products and services, including an increase in direct and
limited distribution;
• the costs, difficulties and uncertainties related to the integration of acquired businesses, including liabilities relating to the operations or activities
of such businesses prior to their acquisition;
• uncertainties relating to our ability to achieve the anticipated results from the acquisition of The Harvard Drug Group;
• risks and uncertainties relating to our pending acquisition of Cordis, including, if completed, the ability to achieve the expected synergies and
positive impact to operating results and the additional risks the Cordis acquisition will subject us to relating to regulatory matters, legal proceedings,
tax laws or positions and global operations, including the effects of local economic environments and currency volatility;
• risks arising from certain of our businesses being Medicare-certified suppliers or participating in state Medicaid programs, which business are
subject to accreditation and quality standards and other rules and regulations, including applicable billing, payment and record-keeping requirements;
• risks arising from certain of our businesses manufacturing or repackaging pharmaceuticals, which businesses are subject to federal and state laws
that establish eligibility for reimbursement by federal and state healthcare programs;
• risks arising from possible violations of the U.S. Foreign Corrupt Practices Act, Chinese anti-corruption laws and other similar anti-corruption laws
in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws;
• risks arising from possible violations of healthcare fraud and abuse laws;
• risks arising from our collecting, handling and maintaining patient-identifiable healthcare information and other sensitive personal information, which
are subject to federal, state and foreign laws that regulate the use and disclosure of such information;